Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of Calgary

$25,000.00

Approach to enhance human antibody expression in plant cells

FY 2017-18

Summary
Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides anattractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an establishedCanadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studiesaimed at delivering an enhanced protein expression technology that can be universally applied to the expressionof any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeuticantibody. This grant will support a new collaborative research project that will test the hypothesis that a novelRNA-binding protein coupled to a translational enhancer can specifically elevate the expression of thisantibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized asequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. Whencoupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of thistherapeutic antibody. Success with this project will result in substantial revenue generation or cost savings toPlantForm, and will further establish the company as an industry leader in plant expression of therapeuticproteins.
Program
Engage Grants Program
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
515077-2017
Name nom
Muench, Douglas
Department département
Biological Sciences
Organization id
11
Institution établissement
University of Calgary
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
5305
Research subject group en
Molecular biology
Research subject group fr
Biologie moléculaire
Research subject en
Protein manipulation and expression
Research subject fr
Expression et recombinaison protéiques
Partie
1
Nb partie
1
Application title
Approach to enhance human antibody expression in plant cells
Keyword
NSERC
Application summary
Plant-based production of high-value therapeutic proteins, such as monoclonal antibodies, provides anattractive alternative to protein expression in mammalian cell systems. PlantForm Corporation is an establishedCanadian company that is supporting the lab of Dr. Douglas Muench at the University of Calgary on studiesaimed at delivering an enhanced protein expression technology that can be universally applied to the expressionof any high value protein of interest. One of PlantForm's most advanced products is a breast cancer therapeuticantibody. This grant will support a new collaborative research project that will test the hypothesis that a novelRNA-binding protein coupled to a translational enhancer can specifically elevate the expression of thisantibody in a plant cell system. The Muench lab at the University of Calgary has recently characterized asequence specific, high affinity RNA-binding protein (APUM23) from the model plant Arabidopsis. Whencoupled to a translational enhancer, APUM23 has the potential to significantly increase the synthesis of thistherapeutic antibody. Success with this project will result in substantial revenue generation or cost savings toPlantForm, and will further establish the company as an industry leader in plant expression of therapeuticproteins.